← ANALYST RATINGS · TIPRANKS
BioAge Labs, Inc. (BIOA): analyst forecast and price target
Analyst consensus
Moderate Buy7 Buy3 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $32.56, the highest $73.00, the lowest $8.00. The average is +572.6% from the last price of $4.84.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.50 → $5.00−9.1% | Hold | +3.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $5.50 → $5.00−9.1% | Hold | +3.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.50 → $5.00−9.1% | Hold | +3.3% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $5.50 → $5.00−9.1% | Sell | +3.3% | Reiterated | 15.10.26on TipRanks 17:05 | — | |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $21.00 | Buy | +333.9% | Reiterated | 14.10.26on TipRanks Oct 15 06:36 | −1.6%next day −1.6% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.00 → $5.50−8.3% | Hold | +13.6% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $6.00 → $5.50−8.3% | Hold | +13.6% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| Name not given | — | $8.00 | Hold | +65.3% | Initiated | 11.10.26on TipRanks Oct 12 05:45 | −6.2%next day −6.2% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $35.00 | Buy | +623.1% | Reiterated | 14.09.26on TipRanks 07:09 | +0.3%next day −3.1% · 5 days −6.5% | ↗ |
| Adam Walsh★★★★★★★★★★#4262 · hits 43% · avg +4.4% | Roth MKM | $25.00 | Buy | +416.5% | Reiterated | 09.09.26on TipRanks 07:50 | −1.9%next day −5.1% · 5 days −14.4% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $23.00 → $20.00−13.0% | Hold | +313.2% | Reiterated | 07.08.26on TipRanks 09:35 | +3.4%next day −2.3% · 5 days −10.0% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $50.00 | Buy | +933.1% | Reiterated | 06.08.26on TipRanks 09:01 | +2.8%next day +3.4% · 5 days −8.7% | ↗ |
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Hold | — | Reiterated | 06.08.26on TipRanks Aug 5 21:25 | +2.8%next day +3.4% · 5 days −8.7% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $73.00 | Buy | +1,408.3% | Assigned | 06.08.26on TipRanks Aug 5 02:50 | −1.8%next day +2.8% · 5 days −4.9% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $40.00 | Buy | +726.4% | Reiterated | 05.08.26on TipRanks Aug 3 07:31 | +17.8%next day +2.1% · 5 days +4.2% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $62.00 → $21.00−66.1% | Buy | +333.9% | Reiterated | 31.07.26on TipRanks 13:50 | −64.3%next day +17.8% · 5 days +26.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering BioAge Labs, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $35.62 at a price of $7.09 (+402.5%); now: $32.56 at $4.84 (+572.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 9 | 13 | 15 | 11 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 4 | 5 | 5 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.64 (from $-0.87 to $-0.47). Last quarter: $-0.58.
Sales
Next quarter’s sales estimate — $1M (from $0M to $3M). Last quarter: $2M.
Best top-analyst consensus in the sector · General
About BioAge Labs, Inc.
- CEO: Kristen Fortney
- Employees: 61
- 5885 Hollis Street, Emeryville, CA, 94608, US
- bioagelabs.com
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Data from the stock’s TipRanks forecast page, read 18 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗